

# WOMEN'S AND MEN'S HEALTH IV PANEL

---

## EDITORIAL BOARD LIAISON

Anne L. Hume, Pharm.D., FCCP, BCPS  
*Professor of Pharmacy*  
Department of Pharmacy Practice  
University of Rhode Island  
Kingston, Rhode Island  
*Adjunct Professor of Family Medicine*  
Alpert School of Medicine at Brown University  
Providence, Rhode Island

## DRUG-INDUCED OSTEOPOROSIS

### Authors

Susan K. Bowles, Pharm.D., MSc, FCCP  
*Associate Professor*  
College of Pharmacy and Department of Medicine  
Dalhousie University  
*Clinical Coordinator – Geriatrics and Mental Health*  
Department of Pharmacy  
Capital District Health Authority  
Halifax, Nova Scotia, Canada

### Reviewers

Mary Beth O'Connell, Pharm.D., FCCP, FASHP, BCPS  
*Associate Professor*  
Department of Pharmacy Practice  
Wayne State University  
Eugene Applebaum College of Pharmacy and  
Health Sciences  
Detroit, Michigan

Michelle M. Richardson, Pharm.D., FCCP, BCPS  
*Special and Scientific Staff*  
William B. Schwartz Division of Nephrology  
Tufts Medical Center  
*Assistant Professor of Medicine*  
Tufts University School of Medicine  
Boston, Massachusetts

## BREAST CANCER TREATMENT-RELATED CARDIOVASCULAR TOXICITY

### Author

Audrea H. Szabatura, Pharm.D., BCOP  
*Oncology Medication Safety Officer*  
Department of Pharmacy  
Dana-Farber Cancer Institute  
Boston, Massachusetts

### Reviewers

Lai Kit Chai, Pharm.D., BCPS  
*Clinical Pharmacist (ICU)*  
Department of Pharmacy  
Kaweah Delta Medical Center  
Visalia, California

Judy W.M. Cheng, Pharm.D., MPH, FCCP, BCPS (AQ  
Cardiology)  
*Professor of Pharmacy Practice*  
Department of Pharmacy Practice  
Massachusetts College of Pharmacy and Health Sciences  
*Clinical Pharmacist*  
Department of Pharmacy  
Brigham and Women's Hospital  
Boston, Massachusetts

Laura Boehnke Michaud, Pharm.D., FASHP, BCOP  
*Manager, Clinical Pharmacy Services*  
Division of Pharmacy  
The University of Texas M.D. Anderson Cancer Center  
Houston, Texas

## DIETARY SUPPLEMENTS IN WOMEN'S AND MEN'S HEALTH

### Authors

Kelly M. Shields, Pharm.D.  
*Associate Professor of Pharmacy Practice*  
Department of Pharmacy Practice  
Raabe College of Pharmacy  
Ohio Northern University  
Ada, Ohio

## **Reviewers**

J. Nile Barnes, Pharm.D., BCPS  
*Clinical Assistant Professor*  
Pharmacy Practice Division  
College of Pharmacy  
The University of Texas at Austin  
Austin, Texas

Marianne McCollum, Ph.D., BSPHarm, BCPS  
*Assistant Dean for Assessment*  
School of Pharmacy  
Rueckert-Hartman College for Health Professions  
Regis University  
Denver, Colorado

Cydny E. McQueen, Pharm.D.  
*Clinical Associate Professor*  
Division of Pharmacy Practice and Administration  
University of Missouri–Kansas City  
School of Pharmacy  
Kansas City, Missouri

***The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 3, Women’s and Men’s Health IV chapters:***

Nicola G. Dahl, Pharm.D.  
*Medical Writer*  
Kanab, Utah

Julia Elenbaas, Pharm.D.  
Belton, Missouri

Mary C. Gurnee, Pharm.D.  
*Pharmacist Consultant*  
Overland Park, Kansas

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** Susan Bowles (Merck Frosst Canada, Ltd.); Thomas Brown (spouse or significant other); Shareen El-Ibiary (ACCP, Women's Health Leadership Council, *Conceive Magazine*); Erika Ernst (American Board of Medical Specialties); Sally Guthrie (Eli Lilly); Jennifer Hagerman (Gilead Sciences); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Michael Klepser (National Institute of Allergy and Infectious Diseases); David Lourwood (Institute for Community Health Education, First Data Bank); Andrea Luisi (Tarascon Pharmacopoeia); William McIntyre (American Cancer Society, American Heart Association); Ian McNicholl (Bristol-Myers Squibb); Cydney McQueen (First Data Bank, Therapeutic Faculties, Inc.); Laura Boehnke Michaud (National Comprehensive Cancer Network, GlaxoSmithKline, ProStrakan, AstraZeneca, Bristol-Myers Squibb); Mary Beth O'Connell (National Institutes of Health, Office of Research on Women's Health, Association of Reproductive Medicine, ASHP); Kelly Ragucci (Wyeth); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation); Martha Stassinis (Veterans Administration); Kristina Ward (Rhode Island Medical Assistance Pharmacy and Therapeutics Committee)

**Stock Ownership:** Lai Kit Chai (Tenet Healthcare Corp.); Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health); Andrea Luisi ([spouse or significant other] Merck, Pfizer, Medco, CVS)

**Royalties:** Lisa C. Hutchison (ASHP); Cydney McQueen (ASHP); Kelly Shields (Pearson Health Sciences)

**Grants:** Susan Bowles (Roche); Judy W.M. Cheng (St. Jude's Medical Research Center); Shareen El-Ibiary (University of California, San Francisco, Roche-Affamatrix); Erika Ernst

(Pfizer Pharmaceuticals [two grants], Merck and Co.); Patty Fan-Havard (Abbott); Alexander Guirguis (Tennessee Department of Health [two grants]); Brian A. Hemstreet (AstraZeneca); Anne Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Courtney Jarvis (Barr Laboratories, Myers Primary Care Institute, University of Massachusetts Medical School/Memorial Medical Center); Michael Klepser (Gilead Sciences); Laura Boehnke Michaud (GlaxoSmithKline, Abraxis Oncology); Mary Beth O'Connell (Merck); Kelly Ragucci (Pfizer, Inc.); Erin C. Raney (Procter and Gamble); Michelle Richardson (NIH NIDDK [two grants]); Justin Sherman (Louisiana Campaign for Tobacco-Free Living); Kristina Ward (Quality Partners of Rhode Island, University of Massachusetts Memorial Healthcare)

**Honoraria:** Susan Bowles (Pfizer Canada, Lundbeck Canada, Merck Frosst Canada, Ltd.); Dana Brown (Pfizer); Thomas Brown (Pfizer, Sanofi-Aventis [spouse or significant other]); Doshia Cummins (Abbot Pharmaceuticals); Shareen El-Ibiary (ACCP, APhA, Florida Agricultural and Mechanical University); Sally Guthrie (Sciis Medical, Bristol-Myers Squibb); Lisa C. Hutchison (ACCP, ASHP); Kristi Kelley (Eli Lilly/Amylin Pharmaceuticals, Pfizer); David Lourwood (Pfizer, Inc., Institute for Community Health Education); Ian McNicholl (Bristol-Myers Squibb, GlaxoSmithKline, Tibotec Therapeutics); Mary Beth O'Connell (Roche); Louise Parent-Stevens (APhA); Erin C. Raney (American Diabetes Association); Michelle Richardson (Amgen); Justin Sherman (ACCP)

**Other: Nothing to Disclose:** J. Nile Barnes, Clarence Chant, Martha Fankhauser, Kelly Killius, Kristen Lamberjack, Marianne McCollum, Anna Morin, Sarah Shrader, Audrea Szabatura

**ROLE OF ACCP:** ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at [www.bpsweb.org/recertification/general.cfm](http://www.bpsweb.org/recertification/general.cfm).

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591  
[www.bpsweb.org](http://www.bpsweb.org)